Drug Trial Radar · NCT06369285
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
225
Planned (sponsor's estimate)
Start
Nov 19, 2024
Primary completion
Dec 30, 2027
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- Puma Biotechnology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. This study is intended to evaluate the optimal alisertib dose administered in combination with the selected endocrine therapy. The study is also planned to evaluate the efficacy, safety, and pharmacokinetics of alisertib in combination with endocrine and to identify the biomarker-defined subgroup(s) that may benefit most from combined alisertib and endocrine therapy. Participants randomized prior to Amendment 4 are randomized 1:1:1 to Arm 1, Arm 2 or Arm 3. Participants randomized under Amendment 4 will be randomized 1:1 to Arm 1 or Arm 2.
Conditions
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Metastatic Breast Cancer
- Recurrent Breast Cancer
Interventions
AlisertibDrug
Alisertib enteric-coated tablets will be taken by mouth twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle.
Endocrine therapyDrug
Investigator selected endocrine therapy will be taken in 28-day dosing cycles according to the approved prescribing information. 1 mg of anastrozole tablet by mouth once daily or 2.5 mg of letrozole tablet by mouth once daily or 25 mg of exemestane tablet by mouth once daily or 20 mg of tamoxifen tablet by mouth once daily or 500 mg of fulvestrant intramuscular injection on Study Day 1, 15, 29, and once every 28 days thereafter
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) Within Dose SubgroupTime frame: From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months
- Duration of Response (DOR) Within Dose SubgroupTime frame: From start date of response (after date of randomization) to first PD, assessed up to 48 months
- Disease Control Rate (DCR) Within Dose SubgroupTime frame: From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months
- Progression Free Survival (PFS) Within Dose SubgroupTime frame: From date of randomization to date of recurrence, progression or death, assessed up to 48 months
- Overall Survival (OS) Within Dose SubgroupTime frame: From date of randomization to death, assessed up to 48 months
- Percentage of Participants With Treatment-Emergent Adverse Events (Adverse Events and Serious Adverse Events) in the Enrolled PopulationTime frame: From date of first dose through last dose plus 28 days, assessed up to 48 months
Locations
53 sites in 3 countries. Site status is shown where the registry gives one.
Alabama Oncology
Birmingham, Alabama · Recruiting
Mayo Clinic Hospital
Phoenix, Arizona · Recruiting
Beverly Hills Cancer Center
Beverly Hills, California · Recruiting
MemorialCare Orange Coast Medical Center
Fountain Valley, California · Recruiting
City of Hope at Orange County Lennar Foundation Cancer Center
Irvine, California · Recruiting
LA Cancer Network
Los Angeles, California · Recruiting
UCLA Department of Medicine - Hematology/Oncology
Los Angeles, California · Recruiting
University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
San Francisco, California · Recruiting
University of Colorado School of Medicine
Aurora, Colorado · Recruiting
Yale University, Yale Cancer Center
New Haven, Connecticut · Withdrawn
Mayo Clinic Florida
Jacksonville, Florida · Recruiting
Cancer Specialists of North Florida
Jacksonville, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Winship Cancer Institute, Emory University
Atlanta, Georgia · Recruiting
University of Illinois Cancer Center
Chicago, Illinois · Recruiting
The University of Chicago
Chicago, Illinois · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
University of Minnesota, Masonic Cancer Center
Minneapolis, Minnesota · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Missouri Cancer Associates
Columbia, Missouri · Recruiting
Saint Luke's Cancer Institute
Kansas City, Missouri · Recruiting
Oncology Hematology Associates
Springfield, Missouri · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Cancer Care Specialists
Reno, Nevada · Recruiting
University of Rochester Medical Center
Rochester, New York · Recruiting
UNC Hospitals, University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
The Ohio State University, Stefanie Spielman Comprehensive Breast Center
Columbus, Ohio · Recruiting
Taylor Cancer Research Center
Maumee, Ohio · Recruiting
Alliance Cancer Specialists
Horsham, Pennsylvania · Recruiting
University of Pennsylvania, Abramson Cancer Center, Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania · Recruiting
University of Pittsburgh (UPMC)
Pittsburgh, Pennsylvania · Recruiting
Tennessee Oncology, Greco-Hainsworth Center for Research
Nashville, Tennessee · Recruiting
Texas Oncology
Dallas, Texas · Recruiting
Virginia Cancer Institute
Richmond, Virginia · Recruiting
Instituto Português de Oncologia de Lisboa Francisco Gentil (IPO Lisboa)
Lisbon, Portugal · Recruiting
Fundação Champalimaud
Lisbon, Portugal · Recruiting
Hospital CUF Descobertas
Lisbon, Portugal · Recruiting
Instituto Português Oncologia Do Porto
Porto, Portugal · Recruiting
Hospital General Universitario Dr. Balmis
Alicante, Spain · Recruiting
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.